On behalf of the Alliance canadienne des patients arthritiques (ACA), we welcomed the opportunity to provide feedback on the draft guidance for biosimilar biologic drugs. Ensuring that patient perspectives are included in the development of policies is essential to improving access, safety, and confidence in treatment options for people living with arthritis.